Core Viewpoint - Immunome, Inc. (IMNM) has seen a 19.1% increase in share price over the past four weeks, closing at $9.49, with analysts projecting a potential upside of 158.2% based on a mean price target of $24.50 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $5.76, indicating variability among analysts [2]. - The lowest price target of $20 suggests an 110.8% increase, while the highest target of $38 indicates a potential surge of 300.4% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, four estimates have been revised upward, leading to a 14.8% increase in the Zacks Consensus Estimate for the current year [12]. - IMNM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13].

Core Viewpoint - Woodward (WWD) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The upgrade for Woodward reflects an improvement in its underlying business, suggesting that investor sentiment may drive the stock price higher [5]. - For the fiscal year ending September 2025, Woodward is expected to earn $6.24 per share, with a 1.6% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [7]. - Woodward's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Group 1 - Shares of Quanex Building Products (NX) have increased by 7.5% over the past four weeks, closing at $20.19, with a mean price target of $37 indicating a potential upside of 83.3% [1] - The mean estimate includes three short-term price targets with a standard deviation of $5.57, where the lowest estimate of $31 suggests a 53.5% increase, and the highest estimate of $42 indicates a potential surge of 108% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 2.8% over the past month [11][12] Group 2 - NX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] - Despite skepticism around the reliability of price targets, the direction implied by them appears to be a useful guide for potential price movements [10]

Core Viewpoint - Perrigo (PRGO) shows potential for significant upside, with a mean price target of $36.67 indicating a 32.9% increase from the current price of $27.60 [1] Price Targets - The average price target consists of three estimates ranging from a low of $30 to a high of $42, with a standard deviation of $6.11, suggesting variability in analyst predictions [2] - The lowest estimate indicates an 8.7% increase, while the highest suggests a 52.2% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment - Analysts exhibit strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 0.1% over the past month, with no negative revisions [12] - PRGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may be misleading, as analysts often set overly optimistic targets due to business incentives [8][10] - Empirical research indicates that price targets rarely predict actual stock price movements, suggesting a need for skepticism [7][10]

Core Viewpoint - Veris Residential (VRE) shares have shown a slight increase of 0.2% over the past four weeks, closing at $15.33, with a potential upside of 25.9% based on Wall Street analysts' mean price target of $19.30 [1][11]. Price Targets and Analyst Estimates - The mean estimate for VRE comprises five short-term price targets with a standard deviation of $4.02, indicating variability among analysts; the lowest estimate suggests a 4.4% increase to $16, while the highest predicts a surge of 69.6% to $26 [2][9]. - Analysts have recently shown increasing optimism regarding VRE's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 2.5% over the past month, with two estimates increasing and no negative revisions [12]. Analyst Behavior and Price Target Reliability - There is skepticism regarding the reliability of analysts' price targets, as empirical research indicates that these targets often mislead investors rather than provide accurate guidance [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations for stocks they cover [8]. - A low standard deviation in price targets suggests a high degree of agreement among analysts about the stock's price direction, serving as a starting point for further research [9]. Investment Ranking - VRE currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [13].

Core Viewpoint - Glaukos (GKOS) shows potential for significant upside, with a mean price target of $128.54 indicating a 34.4% increase from the current price of $95.64, supported by positive earnings estimate revisions [1][11]. Price Targets - The average of 13 short-term price targets ranges from a low of $72 to a high of $182, with a standard deviation of $33.39, indicating variability in analyst estimates [2]. - The lowest estimate suggests a decline of 24.7%, while the most optimistic estimate indicates a potential upside of 90.3% [2]. Analyst Consensus - Analysts have shown strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11]. - The Zacks Consensus Estimate for the current year has increased by 11.8%, with four estimates moving higher and no negative revisions [12]. Zacks Rank - GKOS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Caution on Price Targets - Solely relying on price targets for investment decisions may be misleading, as analysts often set overly optimistic targets influenced by business relationships [3][8][10].

Core Viewpoint - Byrna Technologies Inc. (BYRN) has seen a 16.8% increase in share price over the past four weeks, closing at $28.79, with a potential upside of 26.8% based on Wall Street analysts' mean price target of $36.50 [1] Group 1: Price Targets and Analyst Estimates - The mean price target consists of three short-term estimates with a standard deviation of $3.12, indicating a range of potential outcomes; the lowest estimate suggests a 14.6% increase to $33, while the highest predicts a 35.5% surge to $39 [2] - Analysts' consensus on earnings estimates has improved, with a positive trend in revisions indicating potential upside for BYRN, as historical data shows a strong correlation between earnings estimate revisions and stock price movements [4][11] - The Zacks Consensus Estimate for the current year has increased by 1.5% due to one upward revision and no negative revisions in the last 30 days, reflecting growing optimism among analysts [12] Group 2: Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can mislead investors; empirical research suggests that price targets rarely indicate actual stock price movements [7][8] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price direction, serving as a starting point for further research into fundamental drivers [9] - While price targets should not be the sole basis for investment decisions, they can provide useful directional guidance when considered alongside other factors [10][13]

Group 1 - FuelCell Energy (FCEL) closed at $6.72, with a 57% gain over the past four weeks, and a mean price target of $9.38 indicating a 39.6% upside potential [1] - The average price targets range from a low of $5 to a high of $13.75, with a standard deviation of $3.19, suggesting variability in analyst estimates [2] - Analysts show strong agreement on FCEL's ability to report better earnings, with positive trends in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for FCEL has increased by 0.3% over the past month, indicating a positive outlook with no negative revisions [12] - FCEL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for potential price movements [13]

Core Viewpoint - StoneX Group Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on an upward trend in earnings estimates, which significantly influences stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates in determining near-term stock price movements, making it a valuable tool for investors [2][3]. - Institutional investors utilize earnings estimates to assess the fair value of stocks, leading to significant price movements based on their buying or selling activities [3]. Business Improvement Indicators - The increase in earnings estimates and the Zacks rating upgrade suggest an improvement in StoneX Group's underlying business, which could lead to higher stock prices as investors respond positively [4]. Earnings Estimate Revisions - For the fiscal year ending September 2025, StoneX Group is expected to earn $5.83 per share, with a 0.4% increase in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6]. - The upgrade of StoneX Group to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Core Viewpoint - Sangoma Technologies Corporation (SANG) shows potential for significant upside, with a mean price target of $8.42 indicating a 47.2% increase from the current price of $5.72 [1] Price Targets - The average price target consists of five estimates ranging from a low of $7.94 to a high of $9.50, with a standard deviation of $0.67, suggesting a consensus among analysts [2] - The lowest estimate indicates a potential increase of 38.8%, while the highest suggests a 66.1% upside [2] Analyst Sentiment - Analysts exhibit strong agreement on SANG's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 7.8%, with one estimate moving higher and no negative revisions [12] Zacks Rank - SANG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]